Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18511611 | 0.97 | TLR7 (0.47) | TLR7KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL18511586 | 0.95 | TLR7 (0.50) | TLR7KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL16483207 | 0.89 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL16483288 | 0.85 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL18511632 | 0.85 | TLR7 (0.45) | TLR7KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL18511658 | 0.85 | TLR7 (0.45) | TLR7KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL16483289 | 0.84 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL18511552 | 0.82 | TLR7 (0.58) | TLR7KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL18511546 | 0.82 | TLR7 (0.61) | TLR7KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL18511621 | 0.79 | KCNH2 (0.41) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044169-A1 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044169-A1 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | TYMS, TYMP, DPYD | TLR7 1485/4885KDM4E 1993/4885ALDH1A1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.